Cutaneous small-vessel vasculitis, Efavirenz-resistant virus, Cutaneous examination, Leukocytoclastic vasculitis
According to World Health Organization (WHO), Dolutegravir-based regimen is considered as first-line therapy for PLHIV and strongly recommended for all adults and children at the 10th International AIDS Society Conference on HIV Science (IAS 2019) held in Mexico City. Dolutegravir (integrase inhibitor) is pharmacokinetically favorable with a single daily dose, fewer drug interactions, superior potency against HIV-1, and potency against efavirenz-resistant virus. In 2020, NACO announced the phase-wise replacement of TLE regimen to TLD regimen.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi 